Biology has always been multi-target. Medicine is just catching up

The dominant paradigm in drug development has been: one disease, one target, one drug. For single-target diseases, this works. When a disease has a single dominant driver, a single intervention can be curative. But most diseases are not like this. The biggest unmet needs in medicine are driven by networks.

Fibrosis. Neurodegeneration. Autoimmune disease. Chronic inflammation. The diseases with the biggest unmet need share a common trait: they are not single-pathway diseases. They are driven by multiple biological programs going wrong simultaneously, reinforcing each other in self-sustaining loops. Block one pathway, and the others begin to compensate. The disease adapts and finds an escape route.

This is not a controversial claim. It is the consensus view among researchers who study these diseases. The controversial implication is what it means for drug development: that the single-target approach, which has dominated pharmaceutical R&D for decades, is structurally incapable of solving these problems.

Medicine’s next era belongs to multi-target therapies.

The platform to build them does not exist yet.

We're building the therapeutic platform for multi-target RNA medicines. And alongside it, we're advancing the frontier AI to make it predictive.

From the Table to the Clinic: Uncommon’s Next Chapter in Human Health